Medical anti‐glaucoma therapy: Beyond the drop

Miller, Paul E.; Eaton, Joshua Seth

doi:10.1111/vop.12843

Cited by 30 publications

(24 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…is therapeutic measure could effectively enhance the patient's response to such drugs. In 2020, bimatoprost implants have been approved in the USA for OAG/OHT treatment [53].…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients

Cai

Cao

Liu

et al. 2021

Journal of Ophthalmology

View full text Add to dashboard Cite

Aim. Within the clinical setting, some patients have been identified as lacking in response to PGAs. This meta-analysis study aimed to evaluate the responsiveness of latanoprost, travoprost, bimatoprost, and tafluprost in OAG/OHT patients, latanoprost nonresponders (LNRs), and the IOP-reducing efficacy and safety. Methods. A literature search was conducted on PubMed, Embase, and the Cochrane Controlled Trials Register. The primary clinical endpoint was the number of responders at the end of the study. The secondary clinical endpoint was the IOP reduction at the endpoint from baseline. Safety evaluation included five common adverse events: conjunctival hyperemia, hypertrichosis, ocular burning, ocular itching, and foreign-body sensation. Results. Eleven articles containing ten RCTs were included in this meta-analysis study. The results highlighted that, in the OAG/OHT population, there was no statistically significant difference in the responsiveness of the four PGAs. Bimatoprost had a better IOP-reducing efficacy than latanoprost. There was no significant difference in the IOP-reducing efficacy of travoprost, latanoprost, and tafluprost. In LNRs, the responsiveness of bimatoprost, travoprost, and latanoprost did not show statistical differences. Bimatoprost reduced IOP with a greater extent than latanoprost and travoprost in LNRs, while there was no significant difference in the IOP-reducing efficacy of travoprost and latanoprost. No serious adverse events occurred with the treatment of the four PGAs. The prevalence of conjunctival hyperemia due to bimatoprost or tafluprost was significantly higher than that of latanoprost. Other adverse events had no significant difference between the four drugs. Conclusion. The existing studies cannot prove that latanoprost, travoprost, bimatoprost, and tafluprost have different responsiveness in OAG/OHT patients. Switching to bimatoprost or travoprost cannot achieve a significant improvement in responsiveness in LNRs. Bimatoprost has a better IOP-reducing efficacy than latanoprost and travoprost. No serious adverse events occurred during treatment with any medication we studied.

show abstract

“…is therapeutic measure could effectively enhance the patient's response to such drugs. In 2020, bimatoprost implants have been approved in the USA for OAG/OHT treatment [53].…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients

Cai

Cao

Liu

et al. 2021

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…A phase II human trial has been completed but results have not yet been published, and a phase III study is in progress. 105 Another recently developed intracameral slow-release delivery system utilises biocompatible polycaprolactone as the drug diffusion barrier, 106 and has been used successfully as an intracameral ocular hypotensive carrier in rabbits. 107…”

Section: Intracameral Deliverymentioning

confidence: 99%

Medical therapy for glaucoma: A review

Casson

2022

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

A number of pharmacological targets are exploited to modify the parameters in the Goldmann equation and reduce the intraocular pressure (IOP). This strategy constitutes the foundation for the medical management of glaucoma, the evolution of which, until only recently, has been in relative stagnation. A burst of innovation has produced new ocular hypotensive drugs and longacting delivery methods, including intracameral delivery, which are expanding the clinician's medical armamentarium. A number of IOP-independent neuroprotection strategies have shown strong potential in animal models of glaucoma, but translational attempts have been surprisingly limited. However, while pharmacological options are expanding, the traditional role of topical medical therapy is being challenged by selective laser trabeculoplasty, microinvasive glaucoma surgery, and sustained delivery methods. A scientifically rigorous assessment of new treatments will be critical to empower clinicians with evidence-based information to optimise vision preservation and quality of life outcomes for their patients.

show abstract

“…With various technological advancements, some drugs of various classes-including carbonic anhydrase inhibitors, PG analogs, β-blockers, miotics, α-adrenergic agonists, and hyperosmotics-have been developed. These drugs are responsible for treating glaucomatous complexes either by increasing aqueous humor drainage from the eye or by reducing aqueous humor production [43].…”

Section: Current Pharmaceutical Interventions For the Treatment Of Gl...mentioning

confidence: 99%

Intravitreal Injectable Hydrogels for Sustained Drug Delivery in Glaucoma Treatment and Therapy

Akulo¹,

Adalı

Moyo³

et al. 2022

Polymers

View full text Add to dashboard Cite

Glaucoma is extensively treated with topical eye drops containing drugs. However, the retention time of the loaded drugs and the in vivo bioavailability of the drugs are highly influenced before reaching the targeted area sufficiently, due to physiological and anatomical barriers of the eye, such as rapid nasolacrimal drainage. Poor intraocular penetration and frequent administration may also cause ocular cytotoxicity. A novel approach to overcome these drawbacks is the use of injectable hydrogels administered intravitreously for sustained drug delivery to the target site. These injectable hydrogels are used as nanocarriers to intimately interact with specific diseased ocular tissues to increase the therapeutic efficacy and drug bioavailability of the anti-glaucomic drugs. The human eye is very delicate, and is sensitive to contact with any foreign body material. However, natural biopolymers are non-reactive, biocompatible, biodegradable, and lack immunogenic and inflammatory responses to the host whenever they are incorporated in drug delivery systems. These favorable biomaterial properties have made them widely applicable in biomedical applications, with minimal adversity. This review highlights the importance of using natural biopolymer-based intravitreal hydrogel drug delivery systems for glaucoma treatment over conventional methods.

show abstract

Medical anti‐glaucoma therapy: Beyond the drop

Cited by 30 publications

References 94 publications

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients

Medical therapy for glaucoma: A review

Intravitreal Injectable Hydrogels for Sustained Drug Delivery in Glaucoma Treatment and Therapy

Contact Info

Product

Resources

About